CAMBRIDGE, Mass.--(BUSINESS WIRE)--Targanta Therapeutics Corporation (Nasdaq: TARG) today announced initial efficacy and safety results from its Phase 2 clinical study investigating oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI. Results from this international, multi-center study showed that single and infrequent doses of oritavancin were equally as efficacious and safe as a three-to-seven day course of therapy, the dosing regimen used in two Phase 3 clinical studies in cSSSI caused by gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
